Biomea Fusion, Inc. Common Stock
BMEABiomea Fusion, Inc. (BMEA) is a biopharmaceutical company focused on developing targeted therapies for cancer and rare diseases. The company aims to leverage its precision medicine platform to identify and advance novel drug candidates with the potential to address unmet medical needs in oncology and other therapeutic areas.
Company News
Dr. Ralph DeFronzo presented insights on icovamenib, a potential disease-modifying therapy for diabetes, highlighting its ability to restore beta cell mass and function through menin inhibition during the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease.
Biomea Fusion will present two poster presentations at ObesityWeek® 2025, highlighting preclinical data for BMF-650, an oral GLP-1 receptor agonist, and combination data for icovamenib with semaglutide.
Biomea Fusion, a clinical-stage diabetes and obesity company, will participate in Citi's SMID Biotech C-Suite Fireside Chat Series on October 23, 2025, offering a live audio webcast of the discussion.
Biomea Fusion granted a new employee non-qualified stock options to purchase 48,000 shares of common stock, with shares vesting quarterly over four years under the company's 2023 Inducement Equity Plan.
Biomea Fusion reported a reduced net loss of $20.7 million in Q2 2025, down from $37.3 million in the same period of 2024. The biotechnology company focused on metabolic disease treatments showed progress in cost management and clinical development of its lead drug icovamenib for diabetes and potential obesity treatments.
